SCHEMBL8934331

SCHEMBL8934331

Cc1c[nH]c(=O)c2ccc(OC3CCNCC3)cc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 10/20 0.74
ROCK2 O75116 2/20 0.61
PRKCD Q05655 2/20 0.61
PRKACA P17612 1/20 0.61
PRKG1 Q13976 1/20 0.61
PKN1 Q16512 1/20 0.61
PKN2 Q16513 1/20 0.61
AAK1 Q2M2I8 1/20 0.61
CDC42BPA Q5VT25 1/20 0.61
Q6ZSR9 Q6ZSR9 1/20 0.61
BMP2K Q9NSY1 1/20 0.61
CDC42BPB Q9Y5S2 1/20 0.61
PARP1 P09874 2/20 0.49
PRKX P51817 1/20 0.44
PRKCE Q02156 1/20 0.44
PRKD1 Q15139 1/20 0.44
HRH1 P35367 1/20 0.42
IKBKB O14920 1/20 0.41
PRKCZ Q05513 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8938507 0.88 ROCK1 (0.76) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL4005156 0.85 ROCK1 (1.00) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL4005158 0.85 ROCK1 (1.00) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8934470 0.85 ROCK1 (0.58) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL2574127 0.84 ROCK1 (0.61) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8935105 0.82 ROCK1 (0.60) ROCK1HRH3
SCHEMBL8935086 0.82 ROCK1 (0.60) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8934405 0.80 ROCK1 (0.49) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL8935133 0.80 ROCK1 (0.61) ROCK1HRH1HRH3
SCHEMBL8935088 0.80 ROCK1 (0.58) ROCK1PARP1HRH1HRH3MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910333-B1 PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS SANOFI SA (FR) 2013-05-22 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 ROCK1 8/4885ROCK2 10/4885PRKCD 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.